Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker OKUR
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | Jason A. Leverone Chief Financial Officer | OKUR OnKure Therapeutics, Inc. | Sale | 302 | $2.97 | $897 Sale | Form 4 ↗ |
| Sep 21, 2026 | Nicholas A. Saccomano President and CEO, Director | OKUR OnKure Therapeutics, Inc. | Sale | 87 | $2.97 | $258 Sale | Form 4 ↗ |
| Jun 22, 2026 | Jason A. Leverone Chief Financial Officer | OKUR OnKure Therapeutics, Inc. | Sale | 303 | $4.40 | $1,333 Sale | Form 4 ↗ |
| Jun 22, 2026 | Nicholas A. Saccomano President and CEO, Director | OKUR OnKure Therapeutics, Inc. | Sale | 86 | $4.40 | $378 Sale | Form 4 ↗ |
| Mar 23, 2026 | Jason A. Leverone Chief Financial Officer | OKUR OnKure Therapeutics, Inc. | Sale | 301 | $4.16 | $1,252 Sale | Form 4 ↗ |
| Mar 23, 2026 | Nicholas A. Saccomano President and CEO, Director | OKUR OnKure Therapeutics, Inc. | Sale | 86 | $4.16 | $358 Sale | Form 4 ↗ |
| Dec 22, 2025 | Jason A. Leverone Chief Financial Officer | OKUR OnKure Therapeutics, Inc. | Sale | 302 | $2.97 | $897 Sale | Form 4 ↗ |
| Dec 22, 2025 | Nicholas A. Saccomano President and CEO, Director | OKUR OnKure Therapeutics, Inc. | Sale | 87 | $2.97 | $258 Sale | Form 4 ↗ |
| Sep 22, 2025 | Jason A. Leverone Chief Financial Officer | OKUR OnKure Therapeutics, Inc. | Sale | 303 | $2.62 | $794 Sale | Form 4 ↗ |
| Sep 22, 2025 | Nicholas A. Saccomano President and CEO, Director | OKUR OnKure Therapeutics, Inc. | Sale | 88 | $2.62 | $231 Sale | Form 4 ↗ |
| Jun 23, 2025 | Nicholas A. Saccomano President and CEO, Director | OKUR OnKure Therapeutics, Inc. | Sale | 88 | $2.38 | $209 Sale | Form 4 ↗ |
| Jun 23, 2025 | Jason A. Leverone Chief Financial Officer | OKUR OnKure Therapeutics, Inc. | Sale | 303 | $2.38 | $721 Sale | Form 4 ↗ |
| May 15, 2025 | Acorn Capital Advisors GP, LLC 10% owner | OKUR OnKure Therapeutics, Inc. | Buy | 1.13M | $1.85 | $2.1M Buy | Form 4 ↗ |
| May 15, 2025 | Acorn Capital Advisors GP, LLC 10% owner | OKUR OnKure Therapeutics, Inc. | Buy | 270,270 | $1.85 | $500.0K Buy | Form 4 ↗ |
| May 15, 2025 | Cormorant Private Healthcare Fund III LP | OKUR OnKure Therapeutics, Inc. | Sale | 1.81M | $1.85 | $3.4M Sale | Form 4 ↗ |
| May 12, 2025 | Cormorant Global Healthcare Master Fund, LP 10% owner | OKUR OnKure Therapeutics, Inc. | Sale | 24,300 | $1.99 | $48.4K Sale | Form 4 ↗ |
| Apr 7, 2025 | Nicholas A. Saccomano President and CEO, Director | OKUR OnKure Therapeutics, Inc. | Sale | 516 | $2.67 | $1,378 Sale | Form 4 ↗ |
| Apr 7, 2025 | Jason A. Leverone Chief Financial Officer | OKUR OnKure Therapeutics, Inc. | Sale | 1,844 | $2.67 | $4,923 Sale | Form 4 ↗ |
| Apr 4, 2025 | Nicholas A. Saccomano President and CEO, Director | OKUR OnKure Therapeutics, Inc. | Sale | 358 | $3.33 | $1,192 Sale | Form 4 ↗ |
| Apr 4, 2025 | Jason A. Leverone Chief Financial Officer | OKUR OnKure Therapeutics, Inc. | Sale | 1,278 | $3.33 | $4,256 Sale | Form 4 ↗ |
20 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances